An enhancer sequence found in the Protease Nexin-1 (PN-1) gene was shown to drive lacZ expression speci®cally at the met-/mesencephalic junction in transgenic mouse embryos. A functional study of this enhancer has been performed to better understand the mechanisms regulating isthmic gene expression. An octamer-binding site for POU domain factors was found to be crucial for the activity of the enhancer in vivo. Comparative expression studies of POU domain factors, electrophoretic mobility shift assays and transient transfection experiments, strongly suggest that Brn-1/-2 regulate the enhancer activity in vivo. In addition, in vitro experiments indicated that FGF-8 was required for the maintenance of the enhancer activity, but not for the synthesis of Brn-1/-2. The data represents the ®rst functional evidence for a role of POU factors in the regulation of met-/mesencephalic gene expression. It also implies that at least two regulatory pathways, namely the FGF-8 signaling and the octamer-binding site pathway, synergistically interact to control the PN-1 enhancer activity in vivo. q
Introduction
The met-/mesencephalic territory is an area of the central nervous system (CNS) where developmental processes including tissue patterning and cell differentiation have been extensively investigated. This region includes the prospective met-and mesencephalon which are separated by a neuromeric boundary situated roughly at the isthmic constriction (Bally-Cuif and Wassef, 1995) . During development, this territory gives rise to different brain structures. Caudally, the metencephalon and the isthmic tissue will generate the cerebellum. Rostrally, the mesencephalon will produce the superior and inferior colliculi.
Some of the upstream components of the regulatory cascades that lead to the induction and patterning of the met-/mesencephalic territory have been identi®ed. The expression of the homeobox genes Pax-2, -5 and En-1, -2 in the entire territory indicates that the identities of the metencephalon and the mesencephalon share common features (Stoykova and Gruss, 1994; Rowitch and McMahon, 1995; Wassarman et al., 1997) . Differences are, however, indicated by the asymmetric distribution of the homeobox genes Gbx-2 and Otx-2 in the metencephalon and the mesencephalon, respectively (Boncinelli et al., 1993; Bulfone et al., 1993) . A signaling structure called the met-/mesencephalic organizer is induced at the neuromeric border located at the limit between the expression domain of these two genes (Millet et al., 1996; Acampora et al., 1997; Wassarman et al., 1997) . This organizer plays a decisive role in the patterning of the neural tube rostrally and caudally, by means of secreted molecules like the ®bro-blast growth factor 8 (FGF-8) and WNT-1 (Crossley and Martin, 1995; Hollyday et al., 1995) .
Both secreted molecules and homeobox factors present in each area are synergistically involved in a master regulatory network that determines the identity of the cells in the mesencephalon and metencephalon (McMahon et al., 1992; Bally-Cuif et al., 1995; Lee et al., 1997) . The members of this network are implicated in their mutual regulation that further stabilizes the identity of each indivi- dual area of the met-/mesencephalic territory. The null mutation of any of the members will impair the function of the entire network. In most cases, the tissue becomes respeci®ed and met-/mesencephalic structures are lost or reduced in size (McMahon et al., 1992; Wurst et al., 1994; Ang et al., 1996; Wassarman et al., 1997) .
Although much progress has been made in identifying the members of the network and their genetic interactions, little is known about the regulatory cascades they govern, in particular about the identity of the transcription factors that control downstream genes. Therefore, identi®cation and study of the regulation of such downstream target genes should shed light on this issue.
Protease Nexin-1 (PN-1), a secreted serine protease inhibitor, has been found to be expressed in a ring-like pattern at the embryonic met-/mesencephalic junction as early as 9.5 dpc (Ku Èry et al., 1997 ). The precise pattern of expression, which matched well the pattern of Fgf-8 in this area, offered the opportunity to investigate some of the regulatory pathways governing region-speci®c gene expression at the met-/ mesencephalic junction. We have previously isolated a 1.5 kb enhancer from the 5 H upstream region of the rat PN-1 gene that was capable of targeting lacZ expression to the met-/mesencephalic junction in a PN-1-like manner. Moreover, we showed that FGF-2 was required to maintain the enhancer activity in cultured cells derived from the junction (Ku Èry et al., 1997) . However, the molecular mechanisms governing the expression of the PN-1 enhancer in this area remained to be identi®ed.
In the present study, we describe a 573 bp enhancer within the 1.5 kb regulatory region previously described that, together with the proximal promoter, was necessary and suf®cient for targeting lacZ expression to the met-/ mesencephalic junction. Functional analysis of this enhancer revealed that it contained a consensus octamer-binding site for POU transcription factors crucial for its function. Furthermore, our data strongly suggest that the POU proteins Brn-1 and Brn-2 are the activators of the reporter constructs in vivo, providing ®rst evidence for their implication in region-speci®c gene expression at the met-/mesencephalic junction. The activity of the enhancer was FGF-8 dependent in vitro. In contrast, neither the DNA binding activity nor the expression of Brn-1 and Brn-2 were in¯u-enced by FGF-8 under the same conditions. These data therefore indicate that the octamer binding proteins and the FGF-8 signaling belong to two distinct regulatory pathways that interact synergistically to regulate the PN-1 enhancer activity.
Results

The AccI-PstI fragment of the PN-1 upstream regulatory region is the met-/mesencephalic enhancer
We have previously shown that the genomic DNA fragment situated from 24.3 kb to 22.8 kb in the 5 H upstream regulatory region of the rat PN-1 gene fused to the proximal PN-1 promoter from 20.4 kb to 10.1 kb, was able to direct lacZ expression to the mouse met-/mesencephalic junction (Ku Èry et al., 1997) (arrows in Fig. 1A ) and to the ocular motor nerve (white arrowhead in Fig. 1A ). To investigate the regulatory mechanisms that operate on this construct in vivo, we decided to narrow down a shorter sequence that was necessary and suf®cient to produce speci®c lacZ expression at the isthmus.
A short-term b-galactosidase staining (Fig. 1B) demonstrated that the proximal promoter alone was not suf®cient to reconstitute the met-/mesencephalic expression pattern seen with p2.0/lacZ mice. Instead, it displayed high levels of ectopic staining in the hindbrain folds and the surface ectoderm of the embryo (dotted line in Fig. 1B H ). Therefore, additional fragments of the p2.0/lacZ construct had to be present.
In order to determine which part of the HindIII-PstI region was required to rescue the speci®c met-/mesencephalic staining, we generated transgenes containing either the HindIII-AccI or the AccI-PstI fragments linked to the proximal promoter/lacZ fusion gene. Furthermore, to investigate whether one of these fragments was an enhancer, we linked them to the proximal promoter in a reversed orientation in respect to the wild-type PN-1 gene.
As indicated in Fig. 1C , the AccI-HindIII/proximal promoter/lacZ transgene did not produce any b-galactosidase activity at the junction in vivo. The ocular motor nerve (white arrowhead) was devoid of staining as well. However, the AccI-HindIII fragment was able to ef®ciently suppress the b-galactosidase ectopic staining of the proximal promoter down to the levels seen with the p2.0/lacZ construct. We therefore conclude that this fragment contained silencer elements. In contrast, the p1.0/lacZ transgene containing the PstI-AccI fragment reproduced the b-galactosidase staining at the junction as seen in the p2.0/lacZ transgenic mouse lines (Fig. 1D ). Signals could also be observed in the ocular motor nerve (white arrowhead in Fig. 1D ), the limb and tail buds (data not shown), where p2.0/lacZ was expressed as well. However, the ectopic staining produced by the proximal promoter was not suppressed (dotted line in Fig. 1D ), probably due to the lack of silencer elements found in the HindIII-AccI region. This data shows that the PstIAccI fragment, together with the proximal promoter, is necessary and suf®cient to rescue the met-/mesencephalic expression seen with the p2.0/lacZ transgene irrespective of its orientation. Since it contributed only to the staining in the met-/mesencephalic junction but not elsewhere in the embryo, the AccI-PstI fragment had to be considered a speci®c enhancer for this region.
An octamer-binding site in the met-/mesencephalic enhancer is crucial for its function in vivo
The met-/mesencephalic enhancer was sequenced and The p1.0/lacZ fusion gene was expressed at the met-/mesencephalic junction (arrows) and in the ocular motor nerve (white arrowhead) of transgenic mouse embryos at 11.5 dpc, but did not suppress the extensive ectopic staining produced by the proximal promoter in the hindbrain and the surface ectoderm (dotted line). subjected to a database search. We found several putative binding sites for transcription factors (Fig. 2) . There are ®ve E-boxes for basic helix-loop-helix factors (Prendergast and Ziff, 1991) , four Hox core binding sites for homeodomain proteins (Muller et al., 1988) , two binding sites for the activating protein-1 (AP-1) (Angel et al., 1987) , one for the activating protein-2 (AP-2) , an octamer site (oct) for POU domain factors (Staudt et al., 1986) and a junB-inverted repeat (junB-IR) (de Groot et al., 1991) .
In order to identify functional elements in the enhancer, we decided to analyze the physiological relevance of some of the putative binding sites by site-directed mutagenesis, and to test in vivo whether these mutations affected transgene expression at the junction. Due to the large ectopic ®elds in the hindbrain in the p1.0/lacZ lines, we chose to mutate the enhancer in the p2.0/lacZ construct.
The octamer-binding site, the junB-IR and an AP-1-binding site (bold underlining in Fig. 2 ) were bound by nuclear proteins derived from the met-/mesencephalic territory as assessed by electrophoretic mobility shift assay (EMSA) (data not shown). This suggested a physiological role of these sites. Consequently, they have been mutated separately.
The mutations affected the function of the enhancer to different degrees. The mutation of the octamer-binding site from ATGCAAAT to CGTCAAAT completely abolished lacZ expression in the entire isthmus (Fig. 3A) . However the lacZ staining in the remaining sites targeted by the p2.0/lacZ construct, such as the hindbrain and the limb buds, remained; demonstrating that this octamer-binding site was important for the regulation of expression only at the junction. This particular pattern was seen in 13 out of 14 F 0 embryos. One single F 0 embryo harboring the mutant construct showed lacZ activity around the junction in a much broader area compared to the normal p2.0/lacZ pattern (Table 1 and data not shown). This is likely the result of an integration site effect of the transgene. The mutation of the last three bases of the octamer site from ATGCAAAT to ATGCACCG had identical effects on the transgene expression. This ruled out the possibility that the overlapping E- H ±3 H orientation that it holds in the p1.0/ lacZ transgene. The PstI and AccI restriction sites are identical with the limits of the enhancer fragment as described in Fig. 1A . All putative binding sites are underlined. The binding sites underlined with a bold line have been mutated. The novel nucleic acid sequence data have been deposited in the DDBJ/EMBL/ GenBank Data library under the accession number AJ010385. Fig. 3 . Activity of the mutant PN-1 promoter/lacZ transgenes in stage 11.5 dpc mouse embryos. The mutations introduced into the enhancer are shown to the right of the corresponding expression pattern of the promoter/lacZ construct. The location of the met-/mesencephalic junction is indicated by an arrowhead in all panels. (A) The expression pattern of a p2.0/lacZ construct that has been mutated in the unique octamer site at position 332 of the enhancer lacks any bgalactosidase activity at the met-/mesencephalic junction and ocular motor nerve. LacZ expression is visible in the otic vesicle, in patches of cells in the hindbrain and in the surface ectoderm that covers the midbrain and hindbrain. (B) The mutation of the unique junB-IR at position 388 of the enhancer lead to a loss of dorsal met-/mesencephalic lacZ staining (arrows). The ventral expression remained strong (asterisk) as well as the staining in a few medial stripes of cells and in the ocular motor nerve (white arrowhead). Expression of the transgene also occurred in the otic vesicle and the surface ectoderm. (C) The mutation of the AP-1 site at position 532 in the enhancer lead to a reduction of the dorsal lacZ staining (arrows) without affecting the ventral expression (asterisk) and in the ocular motor nerve (white arrowhead). Both the otic vesicles and the surface ectoderm expressed lacZ. box at CAGATGCAAAT was the physiologically relevant site (three out of three F 0 embryos, data not shown). The mutation of the junB-IR from AGTGCACT to AGTTACCT led, in eight out of ten F 0 embryos, to the loss of the medial and dorsal lacZ staining ( Fig. 3B and Table 1 ). The ventral staining (asterisk) and the staining of the ocular motor nerve (white arrowhead in Fig. 3B ) were unchanged. In the remaining two embryos, the dorsal staining was weak and different from the p2.0/lacZ wild type pattern, arguing for integration site effects. Other sites of expression were not affected by this mutation, indicating that the junB-IR was implicated speci®cally at the junction.
The mutation of the AP-1 site from TGATTAA to TTCGTAA did not affect the expression pattern of the reporter gene consistently. The dorsal staining at the junction was impaired in four out of six F 0 embryos ( Fig. 3C and Table 1 ), leaving unchanged the staining of the ventral side (asterisk) and the ocular motor nerve (white arrowhead in Fig. 3C ). In two out of six F 0 embryos, the pattern of expression was identical to the p2.0/lacZ staining (Table 1 ). These data suggest that the AP-1 site was not crucial to the expression of the reporter gene.
2.3. The met-/mesencephalic nuclear proteins binding to the octamer site are Brn-1, Brn-2, Brn-4 and Oct-1
Having established a key role of the octamer-binding site in the function of the PN-1 enhancer in vivo, next the nuclear proteins present in the met-/mesencephalic tissue and able to speci®cally bind to it had to be identi®ed. We Fig. 4 . Identi®cation of the met-/mesencephalic nuclear proteins binding speci®cally to the octamer site. For each lane the origin of the nuclear proteins, the type of probe used for binding reactions and the antibody are given. The arrowheads identify supershifted complexes. The met-/mesencephalic nuclear factors binding speci®cally to the octamer site produced four major complexes with the probe (lane 1, arrows on the left). The broad band present in all lanes and identi®ed by an asterisk did not involve the octamer site since it was formed also when the octamer site in the probe was mutated (lane 2). Nuclear factors within three of the four complexes formed by the met-/mesencephalic nuclear extracts with the octamer probe were identi®ed using speci®c antibodies against Oct-1 (lane 3), Brn-1 (lane 13) and Brn-2 (lane 8). The antibodies strongly reduced or removed the radioactive signal of the complexes containing these proteins. The Brn-2 complex formed by the met-/mesencephalic extracts (lane 1) was also detected when the octamer probe was incubated with the nuclear extracts of NB2a neuroblastoma cells transfected with Brn-2 (lanes 9 and 10). This complex could be supershifted with antibodies against Brn-2 (lane 10). The fourth speci®c complex formed by the met-/mesencephalic extracts (lane 1) was found to be similar to the one detected when the octamer probe was incubated with nuclear extracts of NB2a cells transfected with Brn-4 (lane 11). Oct-2 and Oct-6 were absent from the met-/mesencephalic tissue, since speci®c antibodies against Oct-2 (lane 4) and Oct-6 (lane 5) did not change the pattern of bandshifts. Oct-6 produced in NB2a cells interacted with the probe (lane 6), forming a complex recognized by antibodies against Oct-6 (lane 7) that was different from those produced with met-/mesencephalic tissue extracts, con®rming the absence of Oct-6 from the met-/mesencephalic extracts. Besides small amounts of Oct-1, no other POU proteins were present in nuclear extracts from NB2a cells transfected with an empty expression vector (lane 12). The free probe is marked by an F.
performed an EMSA using probes identical to the natural enhancer sequence encompassing the octamer-binding site. Five major DNA/protein complexes were formed when the octamer probe was incubated with nuclear extracts from met-/mesencephalic tissue (Fig. 4, lane 1) . A 50-fold excess of cold probe successfully competed with the radioactive probe for binding to the nuclear proteins, showing that the DNA/protein interactions were speci®c (data not shown). The four highest DNA/protein complexes were absent if the octamer site beard the same mutation that abolished isthmic staining in transgenic animals (Fig. 4, lane 2) . Therefore, we concluded that the lowest complex (asterisk in Fig. 4) was not speci®c to the octamer site. In order to identify the proteins in the four remaining complexes we used speci®c antibodies against various POU factors.
Oct-1 was identi®ed in the uppermost band, as antibodies against this protein largely impaired its formation (Fig. 4,  lane 3) . Similarly, the Brn-2 antibodies could interfere with the formation of the second-lowest complex and produced a supershift (lane 8). Brn-2 expressed in NB2a cells formed a complex with the oligomers giving a similar bandshift as the one formed by Brn-2 from the met-/mesencephalic nuclear extracts (lane 9). Also, this complex could be supershifted by antibodies against Brn-2 (lane 10), indicating that POU nuclear proteins expressed either in met-/mesencephalic cells or NB2a cells gave rise to similar complexes with DNA oligomers. Due to the unavailability of speci®c antibodies against Brn-4, we could not provide direct evidence for the presence of this protein in the met-/mesencephalic nuclear extracts. However, Brn-4 was expressed in NB2a Fig. 5 . In situ detection of the mRNA for PN-1 and various POU transcription factors in the met-/mesencephalic territory in stage 11.5 dpc mouse embryos. Neural tubes of the met-/mesencephalic region were dissected, opened dorsally and¯at-mounted. They are shown with the rostral end at the top, and the caudal end at the bottom. The met-/mesencephalic junction is labeled by arrowheads (panels A, B and C) or arrows (panels D and E). (A) PN-1 is expressed at high levels in the dorsal and ventral parts of the junction, but only at very low levels in the medial part of the junction. (B) The mRNA distribution of Brn-1 covers the entire met-/mesencephalic junction and overlaps with the PN-1 expression domain at all levels of the junction. Brn-1 is also present in the metencephalic folds, but it is only weakly expressed in the hindbrain. (C) Brn-2 mRNA is highly expressed in the met-/mesencephalic junction with the exception of the ventral most part, where it is present only at low levels and it is absent from the hindbrain. The Brn-2 expression domain includes the one of PN-1 at all levels of the met-/mesencephalic junction. In contrast, there is no overlap of PN-1 with Brn-4 (D) and Oct-6 (E). cells and the extracts were incubated with the probe (lane 11), giving rise to a complex running parallel to the lowest complex produced speci®cally for the octamer site by met-/ mesencephalic extracts. This observation suggested that Brn-4 was also present in the met-/mesencephalic tissue. Finally, antibodies against Brn-1 could target the second highest complex and thereby produced a supershift (lane 13). Thus, the nuclear proteins in all octamer-binding sitespeci®c complexes formed by the probe and the met-/ mesencephalic nuclear proteins have been identi®ed as Oct-1, Brn-1, Brn-2 and Brn-4.
Despite this fact, we wanted to see whether other POU proteins expressed in the embryonic brain were present in our extracts giving rise to complexes co-migrating with those formed by Brn-1, Brn-2, Brn-4 and Oct-1. Antibodies against Oct-2 (lane 4), Oct-6 (lane 5) and Pit-1 (data not shown) did not change the bandshift pattern or produce a supershift. Moreover, the complex formed with the probe by Oct-6 protein produced in NB2a cells did not resemble any of those produced by met-/mesencephalic nuclear proteins (lane 6). This complex was supershifted with antibodies against Oct-6 (lane 7), proving that we had not induced another POU protein by overexpressing Oct-6 in the NB2a cells. Finally, no other band could be seen besides an Oct-1/ DNA complex if nuclear proteins of untransfected NB2a cells were incubated with the probe (lane 12). These data strongly suggest that the only proteins present in the met-/ mesencephalic tissue capable of binding to the octamer site are Brn-1, Brn-2, Brn-4 and Oct-1.
2.4. The expression domains of Brn-1 and Brn-2 together cover the entire PN-1-positive area of the met-/ mesencephalic junction and these factors transactivate the p2.0/luc construct We then performed whole-mount in situ hybridizations with probes speci®c for each of the POU factors that were binding to the octamer probe in the EMSA, and compared the expression pattern with the one of endogenous PN-1. PN-1 transcripts were detected in a ring-like pattern at the junction, as indicated by the arrowheads (Fig. 5A) . The staining was most intense dorsally and ventrally, with smaller amounts of mRNA found in the medial part. In addition, in the hindbrain several lateral columns and the cells close to the¯oor plate were also found to express PN-1. Rostrally, PN-1-positive cells followed the anterior-posterior axis in the medial part of the neural tube. Both additional expression domains were not found to be coded by the met-/ mesencephalic enhancer (Figs. 1B and 5A). As illustrated in Fig. 5B ,C the domains of expression of Brn-1 and Brn-2 taken together at the junction covered that of PN-1 (arrowheads in B,C). The intensity of the Brn-1/-2 in situ signals detected in the PN-1-expressing domain was not constant. Thus, in the ventral part of the junction the Brn-2 signal was much lower than in more dorsal parts. However, in contrast to the hindbrain, which was found to be devoid of any Brn-2 transcripts, the ventral part of the met-/mesencephalic junction still displayed low amounts of Brn-2 mRNA. The in situ signal for Brn-1 was quite evenly distributed throughout the junction, and thus also found to be present in the ventral part. In contrast, Brn-4 and Oct-6 expression domains were not, or only very marginally, overlapping with the endogenous PN-1 (arrows in D and E).
We then wanted to know whether the POU factors that were co-expressed with PN-1 could indeed stimulate the transcription of the PN-1 promoter transgenes. Transient co-transfections carried out in NB2a (Fig. 6 ) and B104 cell lines (data not shown) showed similar results. The mean values and standard deviations are shown for a typical experiment out of three. As illustrated in Fig. 6A , Brn-1 and Brn-2 but not Oct-1 could transactivate the p2.0/luc construct 5±8-fold, respectively. This transcriptional increase was speci®cally mediated by the octamer-binding site, since upon mutation the upregulation was signi®cantly reduced (Fig. 6B) . 2.5. FGF-8 is required for maintenance of the enhancer activity but not for expression or DNA binding of Brn-1 and Brn-2
Previous data have shown that the FGF signaling was required to maintain the activity of the p2.0/lacZ transgene in met-/mesencephalic cells in vitro (Ku Èry et al., 1997) . Therefore we wanted to know whether FGF-8, the FGFfamily member expressed at the met-/mesencephalic junction, was capable of controlling the synthesis of the POU factors Brn-1 and Brn-2 in the same regulatory pathway. We used the octamer probe to perform an EMSA with nuclear proteins derived from met-/mesencephalic cells cultured for 24 h in the presence (Fig. 7A, right lane) , and in the absence of 40 ng/ml recombinant FGF-8 (left lane). Independent of the presence or absence of FGF-8, we observed DNA/ protein complexes of identical sizes and intensities, indicating that FGF-8 was not involved in the control of expression or DNA binding activity of these POU proteins under these conditions. However, addition of 40 ng/ml FGF-8 was nevertheless required to rescue the loss of activity of the enhancer in cultures of met-/mesencephalic cells derived from p1.0/lacZ transgenic mice (Fig. 7B) . Thus, at least in vitro, both POU factors and the FGF-8 signaling are most likely part of distinct regulatory pathways that are simultaneously required, and therefore synergistically interact to regulate the enhancer activity.
Discussion
3.
1. An octamer-binding site regulates the PN-1 enhancer activity along the entire dorso-ventral axis at the met-/ mesencephalic junction The in vivo expression pattern of the different mutated enhancer constructs revealed that the regulation of the PN-1 enhancer along the entire dorsal-ventral (D/V) axis is under several levels of control. The unique octamer-binding site appeared to be necessary for the function of the enhancer at the whole junction. The strong effect of the mutation on the gene activity in vivo indicated that the octamer-binding site is the target of a global regulatory mechanism that controls expression in the entire junction. In contrast to this, the mutation of the junB-IR affected only the dorsal expression, indicating that it is the target of a dorsal regulatory pathway. This type of regulation has also been described for another target gene of the POU homeodomain factors (Josephson et al., 1998) . There, dorsal hormone signals were implicated in the regulation of the gene nestin in the dorsal mid-and forebrain. The hormone response elements present in the nestin enhancer were different from the junB-IR found in the met-/mesencephalic PN-1 enhancer. However, since in the case of the junB gene the junB-IR site conferred in vitro PKC and PKA responsiveness (de Groot et al., 1991) , it is possible that the junB-IR is the target of extracellular signal(s) operating in the dorsal met-/mesencephalic junction. Unfortunately, the existence and nature of such a mechanism is totally unknown, and evaluation of this hypothesis will require cloning and identi®cation of the junB-IR binding proteins.
The simultaneous need for the octamer site and the junB-IR in the control of enhancer activity suggests that the octamer pathway and a dorsal signal interact at the level of the enhancer to promote transgene expression in a restricted area of the junction. Thus, the octamer-binding site regulates the PN-1 promoter at a global isthmic level and synergizes with further regional pathways that operate in discrete areas along the D/V axis of the junction.
POU factors function in regulatory cascades downstream of key patterning molecules
The present study provides evidence that the crucial role of the octamer site in the regulation of the PN-1 promoter is mediated by the POU proteins Brn-1 and Brn-2. To date, virtually nothing is known about the regulation of the POU factors in the vertebrate met-/mesencephalic territory. In other regions of the CNS, several studies indicate that various POU proteins are required in the regionalization of the neural tube, as well as for the establishment and the differentiation of certain cell phenotypes (Mathis et al., 1992; Nakai et al., 1995; Okazawa et al., 1996; Zwart et al., 1996; Ryan and Rosenfeld, 1997) . In addition, the loss of function experiments of certain POU factors have demonstrated that they might also be involved in the survival of the cells in which they are expressed (Nakai et al., 1995; Schonemann et al., 1995; Erkman et al., 1996; McEvilly et al., 1996) .
In some cases, master regulatory factors patterning the neuroectoderm have been directly implicated in the regulation of POU transcription factors. For instance, Sonic hedgehog (Shh) was found to induce Zp50 in the zebra®sh forebrain (Hauptmann and Gerster, 1996) as well as to down-regulate Brn-3.0 in the chick ventral spinal cord (Fedtsova and Turner, 1997) , whereas retinoic acid affected Pou-2 expression in rhombomeres 2 and 4 of the zebra®sh hindbrain (Hauptmann and Gerster, 1995) . Moreover, recent work in the murine developing diencephalon has shown that the dorsal-ventral signaling gradients produced by Bone Morphogenetic Protein 2 (BMP2) and FGF-8 are causing the limited expression of Brn-4 and Pit-1 (Treier et al., 1998) .
It would thus be of interest to determine the factors that are upstream of the POU proteins at the met-/mesencephalic junction, and to de®ne the pathway that ultimately leads to the expression of PN-1 enhancer/lacZ constructs in vivo. The upstream regulators of the POU factors are likely to be expressed in a region covering the expression domain of these transcription factors. Molecules that ful®l this requirement are homeodomain transcription factors like Otx-2, and Gbx-2 or mesodermal, respectively¯oor plate inductive signals like for instance Shh (Boncinelli et al., 1993; Bulfone et al., 1993; Wassarman et al., 1997) . Clearly, more experiments will be needed to determine the met-/mesencephalic molecules that govern POU factors, and thus to complete the gap between the key regulatory networks and downstream genes like PN-1.
3.3. Multiple regulatory pathways interact to allow the precise PN-1 expression in the met-/mesencephalic territory In spite of the important role of the octamer-binding site in the regulation of the PN-1 promoter at the met-/mesencephalic junction, the expression domains of Brn-1 and Brn-2 argue against them being speci®c isthmic regulators. In fact, as both POU proteins do not activate the expression of p2.0/lacZ outside the junction, they appear to be necessary, but not suf®cient, to trigger high levels of PN-1 enhancer activity in the met-/mesencephalic junction in vivo.
A potential synergistic interaction between the octamer pathway and isthmus-speci®c signals could explain the met-/mesencephalic expression pattern of the enhancer/ lacZ transgenes. For example the POU proteins might require the presence of a co-factor induced by isthmusspeci®c pathways to activate the transcription at high levels. Co-factors have not yet been described for Brn-2, but such proteins exist for other POU proteins like Oct-1, Oct-6 and Brn-1 (Gstaiger et al., 1995; Schubart et al., 1996; Kuhlbrodt et al., 1998) , indicating that the expression of POU proteins is by itself not necessarily suf®cient to explain octamer-binding site-dependent gene expression. Alternatively, isthmic signals could induce a post-translational modi®cation of the POU proteins, like phosphorylation, increasing their af®nity for the octamer-binding site or conferring or enhancing transcriptional activity. Such regulatory mechanisms have, for instance, been demonstrated for some POU factors like Oct-1 (Segil et al., 1991) .
One isthmic signal already shown to have an in¯uence on the PN-1 promoter expression is mediated by FGF-8. The addition of either FGF-2 or FGF-8 was found to be crucial for the maintenance of high levels of lacZ expression in cultured met-/mesencephalic cells derived from p2.0/lacZ or p1.0/lacZ transgenic mice (Ku Èry et al., 1997 and Fig. 7B, respectively) . However, electrophoretic mobility-shift assays showed that the FGF signaling was not able to change the amount, or DNA binding activity, of POU proteins in cultured met-/mesencephalic cells in vitro (Fig.  7A) . We therefore conclude that, at least in vitro, pathways different of FGF-8 regulate the presence of POU proteins in the met-/mesencephalic cells.
Nevertheless, since both the FGF-8 signaling and the octamer-binding site are required for high levels of PN-1 enhancer activity in vitro, a strong synergistic interaction has to be postulated between both regulatory pathways. One possibility is that the FGF-8 signaling enhances the transcriptional activity of octamer-binding proteins speci®cally at the met-/mesencephalic junction. In this case, the octa-mer-binding site would mediate the effect of the FGF-8 signaling. Alternatively, another transcription factor or a co-factor for POU proteins binding somewhere else to the enhancer fragment could be induced by FGF-8. Only the presence of this additional protein would result in POU factors activating transcription by means of protein/protein interactions. Finally, a repressor of the enhancer activity could be downregulated by FGF-8. Further experiments are required to test these possibilities in vivo. Especially the identi®cation of transcriptional activators operating downstream in the FGF pathway in vivo will help clarify the role of the FGF signaling in the regulation of PN-1. In any case, the POU proteins hold a pivotal role in the regulatory events that govern PN-1 enhancer activity at the met-/ mesencephalic junction.
To our knowledge, our data provide the ®rst evidence for an involvement of POU proteins in the region-speci®c gene expression at the met-/mesencephalic boundary. This observation should initiate further studies to de®ne to what extent this class of transcription factors participates in the establishment of the cellular phenotypes at the junction, and to reveal further target genes.
Materials and methods
Site-directed mutagenesis and DNA constructs
The HindIII-PstI region of the rat PN-1 5 H region, harbored in pBluescript KS from Stratagene, was site-directed mutagenized according to the PCR protocol QuickChange by Stratagene. In all cases, three bases have been substituted in order to largely decrease the af®nity of the nuclear proteins to the binding sites (de Groot et al., 1991; Li et al., 1993; Gstaiger et al., 1996) . The PN-1/lacZ reporter genes were constructed by sub-cloning the wild-type or mutant PN-1 regulatory fragments into a promoter-less version of the pSVbGal plasmid (Promega) (Fig. 1A ) (Ku Èry et al., 1997) using the restriction sites mentioned in Fig. 1A . Subsequently, the PN-1/lacZ fusion genes were isolated and puri®ed for microinjection. The PN-1/luciferase constructs were generated by cloning the wild-type or mutated PN-1 genomic fragments into the pPALU vector (Ernù and Monard, 1993) . The expression of the POU transcription factors was achieved by the cloning of the coding region into the pcDNA3.1 vector (Invitrogen). The expression was driven by the cytomegalovirus promoter. The expression vector for Oct-1 was a kind gift of Dr. P. Matthias (Basel), the genomic locus of Brn-1 was obtained from Dr. Hara (Bethesda), the cDNA of Brn-2 was a gift of Dr. C. Goding (London) and the Oct-6 cDNA was obtained from Dr. D. Meijer (Rotterdam).
Generation and analysis of transgenic mice
The transgenic mouse lines were produced as described previously (Ku Èry et al., 1997) . The b-galactosidase activity was detected using the method developed by Zacho and Gossler (1993) .
Electrophoretic mobility-shift assays (EMSA)
The met-/mesencephalic tissue of stage 11.5 dpc mouse embryos derived from matings between C57Bl6 males and CB6F1 females was isolated. The tissue derived from 50±70 embryos was pooled and frozen at 2808C. NB2a mouse neuroblastoma cells, transfected with either the pcDNA3.1 vector containing the open reading frame of POU factors or with the pcDNA3.1 vector devoid of insert, were resuspended, centrifuged and the cell pellet immediately frozen at 2808C.
Nuclear proteins were isolated according to the method of Schreiber et al. (1989) . The DNA oligonucleotide probes were radioactively end-labeled by polynucleotide kinase. The following double stranded oligonucleotides were used (only the upper strand is shown and the wild-type or mutated octamer site are indicated in bold):
Oct: 5
H -CACAACATTACAGATGCAAATCCTGTT-TTGTAA-3 H Oct-mut: 5
H -CACAACATTACAGCGTCAAATCCT-GTTTTGTAA-3 H In binding reactions, either 3 mg of met-/mesencephalic nuclear proteins or 0.7 mg of NB2a-derived nuclear proteins were incubated on ice with 1.7 ng of probe in 50 mM HEPES pH 7.6; 10% Glycerol; 0.01 mM EDTA; 0.1% NP-40; 0.1 M KCl; 3 mg poly[dI-dC] (Boehringer± Mannheim) for 30 min. The DNA/protein complexes were analyzed on 5% polyacrylamide gels. Antibodies against POU proteins were pre-incubated with the nuclear proteins for 15 min on ice, and then the probe was added and incubated on ice for another 15 min. The antibody against Oct-6 was a kind gift of Dr. D. Meijer (Rotterdam). The remaining antibodies were purchased from Santa Cruz Biotechnology.
In situ hybridization
The PN-1 cRNA probe was derived from a 951 bp fragment (BamHI±HindIII) spanning the central part of the mouse PN-1 gene. The mouse Brn-1 probe was derived from the fragment between bases 10 and 705 of the open reading frame. The mouse Brn-2 probe was made from the coding region fragment between bases 1 and 501. The sequence spanning the open reading frame of the mouse Brn-4 gene was ampli®ed by PCR from genomic mouse DNA, and subjected to sequencing in order to detect PCRbased random mutations. The Brn-4 probe corresponded to the bases 1±257 of the open reading frame. Finally, the Oct-6 probe was made from a 500-base-pairs long fragment of the 3 H untranslated region of the mouse Oct-6 gene. All DNA fragments used to generate in situ hybridization probes were sub-cloned into pBluescript vectors (Stratagene) and the antisense digoxygenin uridine triphosphate (DIG-UTP) labeled cRNA probes were transcribed in vitro using T3 or T7 RNA polymerases according to the protocol of the manufacturer (Roche). Whole-mount in situ hybridization was performed as described previously (Ku Èry et al., 1997) using dissected and dorsally opened mid-hindbrains.
Cell transfections
Mouse NB2a or rat B104 neuroblastoma cells grown in Dulbecco's Modi®ed Eagle medium were plated at a density of 50 000 cells per 3.5 cm Petri dish 4 h prior to transfection. The cells were transfected with liposome-based agents as described by the supplier (Roche) and incubated for 16 h. The cells were then washed twice with fresh medium, incubated for another 24 h, harvested and the luciferase (luc) activity measured as described in Ernù and Monard (1993) . The protein amount of each sample was determined according to the method of Schaffner and Weissmann (1973) . All transfections were done in duplicates, and the luciferase activity was standardized to the protein concentration.
Met-/mesencephalic cells culture and FGF-8 treatment
Met-/mesencephalic cells were obtained from tissue explants of p1.0/lacZ transgenic embryos at 11.5 dpc according to the method of Ku Èry et al. (1997) . Cultures were performed as triplicates and mouse recombinant FGF-8b (R&D Systems, UK) was added to the test dishes to a ®nal concentration of 40 ng/ml and the cells were harvested after 24 h. For the EMSA, the test and control dishes were pooled separately to obtain nuclear extracts. For the determination of the activity of the enhancer, the bgalactosidase activity was measured in each individual dish. The values were standardized to the protein content, averaged and plotted. The b-galactosidase activity was determined according to the recommendations of Tropix (Bedford, Massachusetts).
